Yesterday, the Food and Drug Administration handed Impax Laboratories (IPXL +0.00%) a complete response letter, or CRL, for its experimental Parkinson's disease drug Rytary. While an FDA rejection can spell doom for most stocks in the biotech space, shares of Impax only fell around 6% in intraday trading. In this video, health care analysts Max Macaluso and Brenton Flynn discuss this decision and how Impax's diversified portfolio helped to fortify the company against the bad news.
Can Impax Labs Shrug Off This Rejection?
By Max Macaluso and Brenton Flynn – Jan 22, 2013 at 5:45PM
NASDAQ: IPXL
Impax Laboratories
FDA rejection for Impax's Parkinson's disease drug.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo